Eight Things That Will Fix Medtech Investing
This article was originally published in Start Up
Executive Summary
The last five years have been brutal ones for medical device VCs and entrepreneurs, yet there’s still cause for hope. In a series of interviews, we asked venture capitalists, entrepreneurs, and executives: what gives you hope and what makes you optimistic about the future of medtech?
You may also be interested in...
Late-Stage Venture Continues To Dominate Medtech Financing
Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.
SYMPLICITY Results Make Life Difficult For Renal Denervation Programs
The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.
CDRH Preps New Program To Streamline Approval-To-Reimbursement Path
The device center is in the very early stages of launching the “CDRH Reimbursement Program,” planning to go beyond its current parallel-review collaboration with CMS to work with device firms, CMS and private payers to streamline the pathway from market approval to reimbursement.